|
Recent Developments |
|
11-AUG-15
Novartis India, one of the leading pharma companies, Monday said Novartis Healthcare (NHPL) announced the launch of Sequadra Inhaler (indacaterol / glycopyrronium) 110mcg and 50mcg, a fixed dose combination (FDC) of two bronchodilating active ingredients, indacaterol maleate, a long-acting beta2-adrenergic
28-MAY-15
Novartis India disclosed a sharp rise in standalone net profit for the quarter ended March 2015. During the quarter, ... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 30-Sep-2017(6) | 31-Mar-2017(12) | 31-Mar-2016(12) | | Net sales | 2824.70 | 6562.30 | 7889.80 | | Other Income | 477.80 | 490.40 | 829.40 | | Total Income | 3302.50 | 7052.70 | 8719.20 | | Cost of goods sold | 2794.20 | 4716.60 | 7860.10 | | OPBDIT | 508.30 | 2336.10 | 859.10 | | PAT | 331.50 | 572.20 | 1985.00 | | Gross Block | - | - | - | | Equity capital | - | - | 159.80 | | EPS (Rs.) | - | - | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 15.4 | 33.1 | 9.9 | | Net margin (% of OI) | 10.0 | 8.1 | 22.8 |
|
|
Detailed Financials
|
|
|
|
|
